Vanderbilt Clinical Trials

Autoimmune Basis for Postural Tachycardia Syndrome

Purpose

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

Conditions

Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Tachycardia
Arrhythmias, Cardiac
Autonomic Nervous System Diseases
Orthostatic Intolerance
Cardiovascular Diseases
Primary Dysautonomias

Eligibility

Eligible Ages: Between 18 Years and 50 Years
Eligible Genders: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

18-50 years old - Postural Tachycardia Syndrome: Heart rate increase >30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (>20/10 mmHg fall in blood pressure), with chronic symptoms (> 6 months), and in the absence of other acute cause of orthostatic tachycardia. - Able and willing to provide informed consent - Female premenopausal subjects must utilize adequate birth control and willingness to undergo serum beta-hCG testing - The subject must understand and be able to comply with the study procedures and restrictions.

Exclusion Criteria

Hypertension (>150 mmHg systolic and >100 mmHg diastolic) based on history or findings at screening. - Orthostatic hypotension (consistent drop in blood pressure >20/10 mmHg with 10 min stand) - Pregnancy - Cardiovascular disease, such as myocardial infarction within 6 months, angina pectoris, significant arrhythmia (sinus tachycardia is not excluded), deep vein thrombosis, pulmonary embolism - History of serious neurologic disease - History or presence of significant immunological or hematological disorders - Clinically significant gastrointestinal impairment that could interfere with dietary compliance or drug absorption - Impaired hepatic function (aspartate amino transaminase and/or alanine amino transaminase >1.5 x upper limit of normal range) - Impaired renal function (serum creatinine >1.5 mg/dL) - Hematocrit <28% - Current or concurrent disease that could affect the absorption, action or disposition of the drug, or clinical or laboratory assessments. - Any underlying or acute disease requiring regular medication that could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult - Inability to comply with the protocol Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender. We will attempt to study female patients in the first half of their menstrual cycle to minimize cyclical variability.

Study Design

Phase: N/A
Study Type: Interventional
Allocation: N/A
Intervention Model: Single Group Assignment
Primary Purpose: Other
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Autonomic and Antibody Assessments	On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case: Posture study with blood samples for autoantibody testing 24-hour heart rhythm and blood pressure monitoring autonomic function tests Quantitative Axonal Sudomotor Reflex Testing Total blood volume assessment Pharmacologic testing with phenylephrine Pharmacologic testing with isoproterenol Cardiac output with rebreathing Assessment of splanchnic capacitance Microneurography	Drug: phenylephrine Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every ~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg Drug: isoproterenol Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every ~3 min until heart rate increases by 25 bpm. This intervention is optional. Other names: isuprel isoprenaline Radiation: 25 micro-Ci of radiation Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection. Other names: DAXOR Procedure: Posture study with blood samples Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment. Other names: orthostatic challenge orthostatic stress test Procedure: 24-hour heart rhythm and blood pressure monitoring Blood pressure, heart rate and ECG monitoring for 24 hours Other names: 24 Holter Procedure: Quantitative Axonal Sudomotor Reflex Testing The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot. Other names: QSART sweat test Procedure: Autonomic function tests The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output. Other: Rebreathing test Cardiac output will be measured using the rebreathing technique (Innocor) Other names: cardiac output measurement Other: Assessment of splanchnic capacitance Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves Procedure: microneurography microneurography will be measured in the peroneal nerve to assess sympathetic activity. Other names: msna

More Details

Status: Enrolling by invitation
Sponsor: Vanderbilt University Medical Center

Study Contact

Detailed Description

Postural tachycardia syndrome (POTS) is a debilitating disorder resulting from cardiovascular autonomic dysfunction, has many causes and is very difficult to treat effectively. The investigators have identified the presence of autoantibodies (immune proteins) directed against some receptors of the autonomic nervous system that can cause patient's symptoms on standing. The present study is designed to test the hypothesis that patients with POTS harbor functional autoantibodies to adrenergic receptors that lead to an excessive tachycardia characteristic of POTS. For this purpose, this study will define the prevalence, burden, and the in vivo physiological significance of these adrenergic antibodies in a well-phenotyped and representative cohort of patients with POTS and a matched cohort of healthy control subjects, and will characterize the stability of these autoantibodies over time in affected POTS patients.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.